Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Stevanato Group SpA's FCF Margin % or its related term are showing as below:
MEX:STVN N'
s FCF Margin % Range Over the Past 10 Years
Min: -31.02 Med: -5.84 Max: 9.01
Current: -2.41
During the past 8 years, the highest FCF Margin % of Stevanato Group SpA was 9.01%. The lowest was -31.02%. And the median was -5.84%.
MEX:STVN N's FCF Margin % is ranked worse than 55.42% of 812
companies
in the Medical Devices & Instruments industry
Industry Median: -0.53
vs MEX:STVN N: -2.41
The historical data trend for Stevanato Group SpA's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:STVN N vs MMED, TFX, MMSI: FCF Margin % Comparison
For the Medical Instruments & Supplies subindustry, Stevanato Group SpA's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stevanato Group SpA FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Stevanato Group SpA's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Stevanato Group SpA's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stevanato Group SpA (MEX:STVN N) has a FCF Margin % of -11.21% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Stevanato Group SpA and its competitors. According to the industry distribution chart, Stevanato Group SpA ranks #450 out of 812 companies in the Medical Devices & Instruments industry, placing it in the top 55.4%.
Is Stevanato Group SpA's FCF Margin % too high?
Stevanato Group SpA's current FCF Margin % is -11.21%. Based on the distribution chart, Stevanato Group SpA ranks #450 out of 812 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Stevanato Group SpA has a GF Score™ of 86/100, reflecting its overall financial health beyond just this single metric.
How does Stevanato Group SpA's FCF Margin % compare to MMED and TFX?
According to the Medical Devices & Instruments industry distribution chart, Stevanato Group SpA ranks #450 out of 812 companies for FCF Margin %. This places Stevanato Group SpA in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Stevanato Group SpA and its competitors. Stevanato Group SpA's current FCF Margin % is -11.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stevanato Group SpA stock overvalued right now?
Stevanato Group SpA (MEX:STVN N) has a current FCF Margin % of -11.21%. The stock's GF Value™ is MXN315.25, compared to a current price of MXN246.00 — trading 22% below its estimated fair value. The current FCF Margin % is -11.21%. Stevanato Group SpA's overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Stevanato Group SpA (MEX:STVN N), the current FCF Margin % is -11.21% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stevanato Group SpA (MEX:STVN N) Overvalued in 2026?
Based on GuruFocus' analysis, Stevanato Group SpA stock appears to be undervalued.
The current stock price of MXN246.00 is trading 22% below its estimated GF Value™ of MXN315.25.
Key valuation signals for MEX:STVN N:
FCF Margin %: -11.21%
GF Value™: MXN315.25 vs. price of MXN246.00 (22% below fair value)
No single metric tells the full story. See the MEX:STVN N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, It derives its majority revenue from Europe, Middle East and Africa.
86GF Score
Get the complete analysis for MEX:STVN N
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:STVN N has been successfully added to your 
